Insights since FDA Approval of Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea

Curr Sleep Med Rep. 2017 Sep;3(3):133-141. doi: 10.1007/s40675-017-0088-x. Epub 2017 Aug 5.

Abstract

Purpose: The literature on hypoglossal nerve stimulation (HNS) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) was reviewed from 2014, the time of FDA approval for the Inspire Systems device, to 2017 for themes that might be useful conceptually and practically in the consideration of this new non-anatomic surgical therapy.

Recent findings: there are now further follow-up articles since the 12-month results for Apnea Reduction (STAR) trial of the Inspire device, and post-approval publications which report similar and/0r improved AHI outcomes. Other emerging themes include drug-induced sedation endoscopy (DISE) as a tool in assessment of eligibility and a more detailed understanding of mechanisms for an HNS effects.

Summary: The post-STAR literature provides guidelines for an integrated coordination of medicine and surgery to appropriately screen and manage patients.

Keywords: Clinical management OSA; Hypoglossal nerve stimulation; Neurotheraputics; Obstructive sleep apnea.